Quick Answer
Vor Biopharma Inc. reported Operating Income of -$371.64 million for fiscal year 2025.
Vor Biopharma Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$371.64M | -206.7% |
| 2024 | -$121.19M | +3.8% |
| 2023 | -$126.04M | -34.9% |
| 2022 | -$93.42M | -35.4% |
| 2021 | -$69.02M | -59.2% |
| 2020 | -$43.37M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$28.11M | +1.4% | +89.8% |
| June 30, 2025 | -$274.28M | -844.7% | -723.9% |
| March 31, 2025 | -$33.29M | -3.0% | -16.8% |
| September 30, 2024 | -$28.51M | +19.3% | +1.8% |
| June 30, 2024 | -$29.04M | +9.8% | +10.2% |
| March 31, 2024 | -$32.33M | -6.3% | +8.5% |
| September 30, 2023 | -$35.32M | -46.5% | -9.8% |
| June 30, 2023 | -$32.17M | -47.6% | -5.8% |
- Vor Biopharma Inc. showed a decrease of -206.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Vor Biopharma Inc.’s operating income has declined by 757.0% (from -$43.37 million to -$371.64 million).
- The most recent figure is from Vor Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: